BR112013016615A2 - uso de dronedarona para a preparação de um medicamento para uso no controle do risco de lesão hepática - Google Patents

uso de dronedarona para a preparação de um medicamento para uso no controle do risco de lesão hepática

Info

Publication number
BR112013016615A2
BR112013016615A2 BR112013016615A BR112013016615A BR112013016615A2 BR 112013016615 A2 BR112013016615 A2 BR 112013016615A2 BR 112013016615 A BR112013016615 A BR 112013016615A BR 112013016615 A BR112013016615 A BR 112013016615A BR 112013016615 A2 BR112013016615 A2 BR 112013016615A2
Authority
BR
Brazil
Prior art keywords
risk
controlling
liver injury
medicament
preparation
Prior art date
Application number
BR112013016615A
Other languages
English (en)
Inventor
Laurent Auclert
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10306516A external-priority patent/EP2468175A1/en
Priority claimed from EP10306511A external-priority patent/EP2469280A1/en
Priority claimed from EP10306514A external-priority patent/EP2469281A1/en
Priority claimed from EP11305037A external-priority patent/EP2476417A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112013016615A2 publication Critical patent/BR112013016615A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

uso de bronedarona para a preparação de um medicamento para uso no controle do risco de lesão hepática a presente invenção refere-se a um método de controle do risco de lesão hepática em pacientes que recebem o tratamento com dronedarona ou sais farmaceuticamente aceitáveis dos mesmos dos mesmos.
BR112013016615A 2010-12-10 2011-12-09 uso de dronedarona para a preparação de um medicamento para uso no controle do risco de lesão hepática BR112013016615A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US42179810P 2010-12-10 2010-12-10
EP10306516A EP2468175A1 (en) 2010-12-24 2010-12-24 Method for managing the risk of liver injury in patients receiving treatment with dronedarone
EP10306511A EP2469280A1 (en) 2010-12-24 2010-12-24 Method for managing the risk of liver injury in patients receiving treatment with dronedarone
EP10306514A EP2469281A1 (en) 2010-12-24 2010-12-24 Method for managing the risk of liver injury in patients receiving treatment with dronedarone
EP11305037A EP2476417A1 (en) 2011-01-14 2011-01-14 Method for managing the risk of liver injury in patients receiving treatment with dronedarone
PCT/EP2011/072294 WO2012076679A1 (en) 2010-12-10 2011-12-09 Use of dronedarone for the preparation of a drug for use in the management of the risk of liver injury

Publications (1)

Publication Number Publication Date
BR112013016615A2 true BR112013016615A2 (pt) 2016-09-27

Family

ID=45349494

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013016615A BR112013016615A2 (pt) 2010-12-10 2011-12-09 uso de dronedarona para a preparação de um medicamento para uso no controle do risco de lesão hepática

Country Status (13)

Country Link
US (1) US20120190740A1 (pt)
EP (1) EP2649453A1 (pt)
JP (1) JP2013544870A (pt)
KR (1) KR20140091645A (pt)
CN (1) CN103328983A (pt)
AU (1) AU2011340488A1 (pt)
BR (1) BR112013016615A2 (pt)
CA (1) CA2818277A1 (pt)
IL (1) IL226471A0 (pt)
MX (1) MX2013006564A (pt)
RU (1) RU2013131761A (pt)
SG (1) SG190711A1 (pt)
WO (1) WO2012076679A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3195862A1 (en) 2008-04-17 2017-07-26 Sanofi Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation
KR20190078591A (ko) 2016-11-22 2019-07-04 니폰 제온 가부시키가이샤 중합성 화합물, 중합성 조성물, 고분자, 광학 필름, 광학 이방체, 편광판, 플랫 패널 표시 장치, 유기 일렉트로루미네센스 표시 장치, 반사 방지 필름, 및 화합물
US20190322936A1 (en) 2016-12-27 2019-10-24 Zeon Corporation Polymerizable compound, polymerizable liquid crystal mixture, polymer, optical film, optically anisotropic body, polarizer, display, antireflection film, and compound
WO2018168778A1 (ja) 2017-03-17 2018-09-20 日本ゼオン株式会社 重合性化合物、重合性液晶混合物、高分子、光学フィルム、光学異方体、偏光板、表示装置、反射防止フィルム、および化合物
CN110392703B (zh) 2017-03-23 2022-02-01 日本瑞翁株式会社 聚合性化合物及其制造方法、聚合性组合物、高分子、光学膜、光学各向异性体
EP3674757B1 (en) 2017-08-23 2022-04-20 Zeon Corporation Polymerizable liquid crystal material, polymerizable liquid crystal composition, polymer, optical film, optical anisotropic body, polarizer, antireflective film, display device and method for manufacturing polymerizable liquid crystal composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
CN100560067C (zh) * 2006-09-29 2009-11-18 北京德众万全药物技术开发有限公司 盐酸决奈达隆口服药物组合物及其制备方法
FR2959132A1 (fr) * 2010-04-22 2011-10-28 Sanofi Aventis Procedes pour l'evaluation et la reduction des risques

Also Published As

Publication number Publication date
AU2011340488A1 (en) 2013-06-27
CA2818277A1 (en) 2012-06-14
WO2012076679A1 (en) 2012-06-14
EP2649453A1 (en) 2013-10-16
US20120190740A1 (en) 2012-07-26
RU2013131761A (ru) 2015-01-20
KR20140091645A (ko) 2014-07-22
JP2013544870A (ja) 2013-12-19
CN103328983A (zh) 2013-09-25
SG190711A1 (en) 2013-07-31
MX2013006564A (es) 2013-08-26
IL226471A0 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112015008447A2 (pt) métodos para tratar câncer
BR112015003590A8 (pt) Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r
BR112014018953A8 (pt) Derivados de lupano triterpenoide e uso farmacêutico dos mesmos
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BR112014000371A2 (pt) derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
BR112015014585A2 (pt) composto, composição farmacêutica, e, método de tratamento de um ser humano
BR112013016615A2 (pt) uso de dronedarona para a preparação de um medicamento para uso no controle do risco de lesão hepática
BR112013030045A2 (pt) composto da fórmula d-m-d ou um sal farmacêuticamente aceitável do mesmo; composto ou sal; composição farmacêutica; e método de tratamento de infecção por hepatite c em um paciente
BR112015002858A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para prevenir, controlar, tratar ou atenuar uma doença viral ou uma doença por hbv em um paciente
BR112013007681A2 (pt) uso terapêutico de um agonista trl e terapia de combinação
BR112012005225B8 (pt) Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
BR112015008365A2 (pt) composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
BR112012029653A2 (pt) formulação tópica para um inibidor jak
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
BR112014011850A2 (pt) derivados de aminopirimidina como moduladores de lrrk2
BR112014005407A2 (pt) composto, composição farmacêutico, uso do composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de um paciente infectado com hcv
BR112014007902A2 (pt) composições farmacêuticas compreendendo 40-o-(2-hidróxi)etil-rapamicina
BRPI0906444B8 (pt) compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
BR112013011480A2 (pt) método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]